ACAD Q2 2023 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$165M+22.8% YoY

Gross Profit

$158M95.5% margin

Operating Income

$3M1.8% margin

Net Income

$1M0.7% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+39.5%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$643M

Total Liabilities

$247M

Stockholders' Equity

$396M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$135M	+22.8%
Gross Profit	$158M	$132M	+19.6%
Operating Income	$3M	-$34M	+109.0%
Net Income	$1M	-$34M	+103.3%